| Trial ID: | L0185 |
| Source ID: | NCT03803514
|
| Associated Drug: |
Recombinant Epo
|
| Title: |
Effect of rEPO in FGF23 in ESRD Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia|Chronic Kidney Diseases
|
| Interventions: |
DRUG: Recombinant EPO
|
| Outcome Measures: |
Primary: Changes in plasma intact FGF23 levels, Measurements of plasma intact FGF23 levels, 12 weeks | Secondary: Changes in plasma C-terminal FGF23 levels, Measurements of plasma C-terminal FGF23 levels, 12 weeks|Changes in hematocrit and hemoglobin, Measurements of hematocrit and hemoglobin in blood samples, 12 weeks|Changes in parathormone levels, Measurements of parathormone levels in blood samples, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Chile
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2017-08-15
|
| Completion Date: |
2019-10-20
|
| Results First Posted: |
|
| Last Update Posted: |
2020-05-27
|
| Locations: |
Hospital Clinico Universidad de Chile, Santiago, Chile
|
| URL: |
https://clinicaltrials.gov/show/NCT03803514
|
